Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.52 |
| ▸ | HTR6 | P50406 | 4/20 | 0.50 |
| ▸ | HTR2B | P41595 | 10/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747129 | 0.89 | HTR2C (0.56) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL10249403 | 0.83 | HTR2C (0.50) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL5743799 | 0.82 | HTR2C (0.51) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL692398 | 0.79 | HTR2C (0.46) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL5744369 | 0.79 | HTR2C (0.56) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL2016529 | 0.77 | HTR2C (0.46) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL2562895 | 0.77 | HTR2C (0.46) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL2015096 | 0.76 | HTR2C (0.48) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL5748262 | 0.75 | HTR2C (0.52) | HTR2CHTR6HTR2BHTR2A | |
| SCHEMBL30729380 | 0.74 | MEN1 (0.64) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345942-B9 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1345942-B1 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6638934-B2 | 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-28 | — | — | US | disclosed |
| US-20020177596-A1 | Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177596-A1 | Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands | HTR1A, HTR5A, HTR1D | HTR2C 6/4885HTR6 20/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.